著者
那須 勝
出版者
The Japanese Society of Internal Medicine
雑誌
日本内科学会雑誌 (ISSN:00215384)
巻号頁・発行日
vol.87, no.9, pp.1904-1909, 1998-09-10
被引用文献数
2
著者
Sadatomo Tasaka Hitoshi Tokuda Fumikazu Sakai Takeshi Fujii Kazuhiro Tateda Takeshi Johkoh Norio Ohmagari Hiromitsu Ohta Hideki Araoka Yoshimi Kikuchi Masahide Yasui Kanako Inuzuka Hajime Goto
出版者
The Japanese Society of Internal Medicine
雑誌
Internal Medicine (ISSN:09182918)
巻号頁・発行日
vol.49, no.4, pp.273-281, 2010 (Released:2010-02-15)
参考文献数
21
被引用文献数
24 63

Background The clinical features of pneumocystis pneumonia (PCP) differ according to the predisposing factors responsible for immunosuppression. Although PCP in patients with acquired immunodeficiency syndrome (AIDS) has been extensively described, its characteristics in non-AIDS patients, such as those with malignancies, are not thoroughly documented. Study objective To characterize and compare the clinical and imaging features of PCP in patients with malignancies with those in AIDS patients. Design A multi-center retrospective study. Patients and Measurements We evaluated the clinical and radiological features of PCP in 21 patients with malignancies and in 17 with AIDS. Clinical presentation, serum markers, oxygenation, CT findings, and outcome were examined. Results The patients with malignancies showed shorter durations of symptoms before PCP was diagnosed. The levels of serum markers and the oxygenation index did not differ. CT showed diffuse or widespread ground-glass opacity (GGO) in all of the patients evaluated. None of the AIDS patients demonstrated consolidation, whereas half of the patients with malignancy showed consolidation along with GGO. The extent of GGO scored on CT images was significantly greater in the AIDS patients. No correlation was observed between the CT findings and other clinical parameters. All of the AIDS patients recovered from PCP, whereas six patients with malignancies died within a month after the onset of PCP. Conclusion The characteristics of the CT images differed between the patient groups with different underlying disorders, although it remains to be determined whether CT findings are associated with other clinical features or are predictive of the outcome of PCP.
著者
石野 祐三子 菅野 健太郎
出版者
The Japanese Society of Internal Medicine
雑誌
日本内科学会雑誌 (ISSN:00215384)
巻号頁・発行日
vol.94, no.12, pp.2508-2513, 2005-12-10
被引用文献数
2

消化管疾患,特に悪性疾患の早期診断に有用な検査として,胃癌については発癌リスク評価としての血清ペプシノゲン法,ヘリコバクター・ピロリ抗体検査がある.いずれも胃癌の青景因子である萎縮性胃炎を評価し,発癌高危険群の囲い込みに有用である.また大腸癌については便潜血反応の有効性が確立している.更に便中遺伝子変異を検出することで癌の局在診断に結びつけようとする研究も進んでおり,今後の進展が期待される.
著者
後藤 暁 藤森 一也 金児 泰明 赤松 泰次
出版者
The Japanese Society of Internal Medicine
雑誌
日本内科学会雑誌 (ISSN:00215384)
巻号頁・発行日
vol.87, no.5, pp.863-867, 1998-05-10
被引用文献数
2 1

<i>Helicobacter pylori</i>の血清診断,尿素呼気試験は非侵襲的で,感染診断のスクリーニングには十分な精度がある.血清抗体価は除菌成功後は経時的に低下することから,治療後のモニタリングにも有用である.血清ペプシノーゲン値も治療に伴い早期から変動し,治療効果の指標の一つとなり得る.尿素呼気試験は測定法等に解決すべき点は残されているものの,その正確性から除菌判定のスタンダードとされている.
著者
Ito Michiko Hanaoka Masayuki Droma Yunden Hatayama Orie Sato Etsuro Katsuyama Yoshihiko Fujimoto Keisaku Ota Masao
出版者
The Japanese Society of Internal Medicine
雑誌
Internal Medicine (ISSN:09182918)
巻号頁・発行日
vol.47, no.15, pp.1387-1394, 2008
被引用文献数
1 29

<b>Objective</b> The transforming growth factor beta-1 gene (<i>TGFB1</i>) is one of the most promising candidate genes for chronic obstructive pulmonary disease (COPD). Several case-control studies have been performed and generated inconsistent results. The possible reasons for these discrepancies include the diversity of ethnic populations and the heterogeneity of COPD, including emphysema and airway disease. We designed this study to investigate the association of single nucleotide polymorphisms (SNPs) of <i>TGFB1</i> with the emphysema phenotype in the Japanese population.<br> <b>Methods</b> Eight SNPs in <i>TGFB1</i> (<i>rs2241712</i>, <i>rs1982072</i>, and <i>rs1800469</i> in the promoter region; <i>rs1982073</i> in exon 1; <i>rs2241716</i> and <i>rs4803455</i> in intron 2; <i>rs6957</i> and <i>rs2241718</i> in the 3' region) were genotyped by allelic discrimination assays in 70 COPD patients with emphysema phenotype and 99 healthy smokers. The emphysema phenotype was identified by high-resolution computed tomography imaging using Goddard's method.<br> <b>Results</b> The frequency of one significant haplotype structured by the eight SNPs was significantly higher in the emphysema group (10%) than in the healthy smokers (4%, p=0.02). In the emphysema group, the predicted value of forced expiratory volume in 1 second after bronchodilator administration was significantly associated with the minor alleles of the two SNPs (<i>rs1800469</i> and <i>rs1982073</i>, p=0.007 and 0.032, respectively), however, the low attenuation area and carbon monoxide diffusing capacity were not associated with the SNPs. In addition, the <i>rs1800469T</i> and <i>rs1982073C</i> alleles were significantly more prevalent in patients with severe and very severe airflow limitation than in those with mild and moderate airflow limitation (p=0.007 and 0.041, respectively).<br> <b>Conclusions</b> One significant haplotype of <i>TGFB1</i> is associated with the emphysema phenotype in the Japanese population. Two <i>TGFB1</i> SNPs (<i>rs1800469</i> and <i>rs1982073</i>) are associated with the severity of COPD in patients with emphysema phenotype.<br>
著者
Sahin Mustafa Kebapcilar Levent Taslipinar Abdullah Azal Omer Ozgurtas Taner Corakci Ahmet Akgul Emin Ozgur Yavuz Taslipinar Mine Yazici Mahmut Kutlu Mustafa
出版者
The Japanese Society of Internal Medicine
雑誌
Internal Medicine (ISSN:09182918)
巻号頁・発行日
vol.48, no.1, pp.33-39, 2009
被引用文献数
21

<b>Objective</b> Obesity is currently a major public health problem and one of the potential underlying causes of obesity in a minority of patients is Cushing's syndrome (CS). Traditionally, the gold standard screening test for CS is 1 mg dexamethasone overnight suppression test. However, it is known that obese subjects have high false positive results with this test.<br> <b>Design</b> We have therefore compared the 1 mg and 2 mg overnight dexamethasone suppression tests in obese subjects. Patients whose serum cortisol after ODST was >50 nM underwent and a low-dose dexamethasone suppression test (LDDST); 24-hour urine cortisol was collected for basal urinary free cortisol (UFC). For positive results after overnight 1-mg dexamethasone suppression test we also performed the overnight 2-mg dexamethasone suppression test.<br> <b>Patients</b> We prospectively evaluated 100 patients (22 men and 78 women, ranging in age from 17 to 73 years with a body mass index (BMI) >30 kg/m<sup>2</sup> who had been referred to our hospital-affiliated endocrine clinic because of simple obesity. Suppression of serum cortisol to <50 nM (1.8 μg/dL) after dexamethasone administration was chosen as the cut-off point for normal suppression.<br> <b>Measurements</b> Thyroid function tests, lipid profiles, homocysteine, antithyroglobulin, anti-thyroid peroxidase antibody levels, vitamin B12, folate levels, insulin resistance [by homeostasis model assessment (HOMA)] and 1.0 mg postdexamethasone (postdex) suppression cortisol levels were measured.<br> <b>Results</b> We found an 8% false-positive rate in 1 mg overnight test and 2% in 2 mg overnight test (p=0.001). There was no correlation between the cortisol levels after ODST and other parameters.<br> <b>Conclusions</b> Our results indicate that the 2 mg overnight dexamethasone suppression test (ODST) is more convenient and accurate than 1-mg ODST as a screening test for excluding CS in subjects with simple obesity.<br>